EP Patent

EP2272536A2 — Hot-melt extrudable Pharmaceutical formulation

Assigned to University of Texas System · Expires 2011-01-12 · 15y expired

What this patent protects

The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a higher molecular weight poly(ethylene oxide). In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention …

USPTO Abstract

The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a higher molecular weight poly(ethylene oxide). In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention also includes methods for hot-melt extruding pharmaceutical formulations.

Drugs covered by this patent

Patent Metadata

Patent number
EP2272536A2
Jurisdiction
EP
Classification
—
Expires
2011-01-12
Drug substance claim
No
Drug product claim
No
Assignee
University of Texas System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.